Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Solvanix

Solvanix
2015 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$1.63M LATEST DEAL AMOUNT
1 INVESTORS
Description

Provider of biotechnology services in Australia. The company provides novel technology for improving stability and reducing the aggregation of fully human antibodies.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 384 Victoria Street
  • Darlinghurst, New South Wales 2010
  • Australia

+61 0000000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Solvanix’s full profile, request a free trial.

Solvanix Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 15-Jan-2015 $1.63M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Solvanix Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Brandon Capital Partners Venture Capital Minority 000 0000 000000 0

Solvanix Executive Team (2)

Name Title Board
Seat
Contact
Info
Daniel Christ Ph.D Chief Scientific Officer & Founder
Philip Wallace Ph.D Head, Product and Business Development

Solvanix Board Members (3)

Name Representing Role Since Contact
Info
Christina Hardy Solvanix Board Member 000 0000
Christopher Smith Ph.D Brandon Capital Partners Board Member 000 0000
Jenny Harry Ph.D Self Non-Executive Director 000 0000